Tags

Type your tag names separated by a space and hit enter

Reversible contraception for the woman over 35 years of age.
Curr Opin Obstet Gynecol. 1992 Dec; 4(6):891-6.CO

Abstract

Methods of reversible contraception, oral contraceptives, intrauterine devices, and Norplant (systemic progestin-only contraceptive; Wyeth-Ayerst, Radnor, PA), can be used for women over 35 years of age. Oral contraceptive formulations are safe and effective for healthy women up to the age of menopause. Oral contraceptives in women who do not smoke cigarettes do not result in a significant increased risk for cardiovascular disease. The incidence of breast cancer is not increased in women who have used oral contraceptives. A slight increase was found in younger women who had been on oral contraceptives based on a reanalysis of the contraceptive and steroid hormone study of the Centers for Disease Control. A reduction in the incidence of ovarian epithelial neoplasia by 40% was found in three European case-control studies. Two intrauterine devices are currently available on the US market: Paragard (GynoPharma, Somerville, NJ) and Progestasert (Alza Corp., Palo Alto, CA). Both of these provide highly effective contraception. A World Health Organization prospective randomized study found that there was an increase in pelvic inflammatory disease rates in the first 20 days after intrauterine device insertion. The intrauterine device itself did not increase the pelvic inflammatory disease incidence rates. The Norplant system exerts its contraceptive action through ovulation inhibition and alteration of cervical mucus. The major consumer complaint is irregular or prolonged uterine bleeding, which can be controlled by oral estrogen.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk 23507-1912.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1450355

Citation

Archer, D F.. "Reversible Contraception for the Woman Over 35 Years of Age." Current Opinion in Obstetrics & Gynecology, vol. 4, no. 6, 1992, pp. 891-6.
Archer DF. Reversible contraception for the woman over 35 years of age. Curr Opin Obstet Gynecol. 1992;4(6):891-6.
Archer, D. F. (1992). Reversible contraception for the woman over 35 years of age. Current Opinion in Obstetrics & Gynecology, 4(6), 891-6.
Archer DF. Reversible Contraception for the Woman Over 35 Years of Age. Curr Opin Obstet Gynecol. 1992;4(6):891-6. PubMed PMID: 1450355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reversible contraception for the woman over 35 years of age. A1 - Archer,D F, PY - 1992/12/1/pubmed PY - 1992/12/1/medline PY - 1992/12/1/entrez KW - Adnexitis KW - Age Factors KW - Americas KW - Biology KW - Breast Cancer KW - Cancer KW - Cervical Mucus KW - Cervix KW - Contraception KW - Contraceptive Implants KW - Contraceptive Methods KW - Contraceptive Methods--beneficial effects KW - Contraceptive Mode Of Action KW - Demographic Factors KW - Developed Countries KW - Diseases KW - Family Planning KW - Genitalia KW - Genitalia, Female KW - Infections KW - Iud KW - Iud, Copper Releasing KW - Iud, Hormone Releasing KW - Literature Review KW - Menstruation Disorders KW - Neoplasms KW - North America KW - Northern America KW - Oral Contraceptives, Low-dose--beneficial effects KW - Oral Contraceptives--beneficial effects KW - Ovarian Cancer--prevention and control KW - Ovarian Cysts--prevention and control KW - Ovulation Suppression KW - Pelvic Inflammatory Disease KW - Physiology KW - Population KW - Population Characteristics KW - Reproductive Tract Infections KW - Reversibility KW - United States KW - Urogenital System KW - Uterus SP - 891 EP - 6 JF - Current opinion in obstetrics & gynecology JO - Curr. Opin. Obstet. Gynecol. VL - 4 IS - 6 N2 - Methods of reversible contraception, oral contraceptives, intrauterine devices, and Norplant (systemic progestin-only contraceptive; Wyeth-Ayerst, Radnor, PA), can be used for women over 35 years of age. Oral contraceptive formulations are safe and effective for healthy women up to the age of menopause. Oral contraceptives in women who do not smoke cigarettes do not result in a significant increased risk for cardiovascular disease. The incidence of breast cancer is not increased in women who have used oral contraceptives. A slight increase was found in younger women who had been on oral contraceptives based on a reanalysis of the contraceptive and steroid hormone study of the Centers for Disease Control. A reduction in the incidence of ovarian epithelial neoplasia by 40% was found in three European case-control studies. Two intrauterine devices are currently available on the US market: Paragard (GynoPharma, Somerville, NJ) and Progestasert (Alza Corp., Palo Alto, CA). Both of these provide highly effective contraception. A World Health Organization prospective randomized study found that there was an increase in pelvic inflammatory disease rates in the first 20 days after intrauterine device insertion. The intrauterine device itself did not increase the pelvic inflammatory disease incidence rates. The Norplant system exerts its contraceptive action through ovulation inhibition and alteration of cervical mucus. The major consumer complaint is irregular or prolonged uterine bleeding, which can be controlled by oral estrogen. SN - 1040-872X UR - https://www.unboundmedicine.com/medline/citation/1450355/Reversible_contraception_for_the_woman_over_35_years_of_age_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=1450355.ui DB - PRIME DP - Unbound Medicine ER -